ORCHIDPHAR

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange that the Allotment Committee of the Board of Directors at their meeting held on December 22, 2014 has allotted 1,48,09,801 equity shares of Rs. 10/- each @ Rs.49.79/- (Including a premium of Rs. 39.79/- per share) as the first tranche to the Promoter group Company M/s. Orchid Healthcare Private Limited on Preferential Basis as per the Corporate Debt Restructuring (CDR) Scheme approved by the CDR Empowered Group in terms of CDR Scheme.

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange that Allotment Committee of Board of Directors is proposed to be held on December 22, 2014 to allot shares on Preferential Basis to Orchid Healthcare Private Limited.

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange that Industrial Development Bank of India has withdrawn the nomination of Shri T A Ganesh and nominated Shri Nagaraj Garla on the Board of Company.

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange regarding a press release with respect to Financial Results for the Quarter ended September 30, 2014 (Q4 FY15).

Orchid Chemicals & Pharmaceuticals Limited has submitted to the exchange the standalone financial results along with the Limited Review Report for the period ended 30-Sep-2014.

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange regarding extension of Financial Year for 2013-2014 up to 18 Months

K. Raghavendra Rao has submitted to the Exchange, vide letter dated August 19, 2014 a copy of Disclosure in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Orchid Chemicals & Pharmaceuticals Limited has submitted to the exchange the standalone financial results along with the Limited Review Report for the period ended 30-Jun-2014.

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange that the Board of Directors at its meeting held on July 14, 2014 has approved the delisting of the equity shares from Madras Stock Exchange Limited, pursuant to voluntary de recognision and exit of Madras Stock Exchange Limited as per the Securities and Exchange Board of India's (SEBI) circular dated May 30, 2012.

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange regarding the Outcome of the Board Meeting held on July 14, 2014.

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange regarding the Implementation of the CDR package Company consummates the business transfer agreement with Hospira

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange regarding a Press Release dated June 19, 2014 titled "Orchid receives US FDA approval for Eszopiclone Tablets ANDA".

Spurt in Volume : Substantial increase in trading volumes have been observed in Orchid Chemicals & Pharmaceuticals Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Orchid Chemicals & Pharmaceuticals Limited has vide its letter inter-alia stated,"We confirm that there are no material developments and plans other than those already communicated to the exchanges in line with the listing agreement. The company is unaware of the

K Raghavendra Rao has submitted to the Exchange vide letter dated May 14, 2014 a copy of Disclosure in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Orchid Chemicals & Pharmaceuticals Limited has informed that in the meeting of the board held on May 12, 2014, Shri. K N Venkatasubramanian, (Non-Executive, Independent Director) has been designated as the Chairman of the Company and consequent to this, Shri K. Raghavendra Rao has been re-designated as the Managing Director of the Company.

Orchid Chemicals & Pharmaceuticals Limited has submitted to the exchange the standalone financial results for the period ended 31-mar-2014.

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange that Shri K N Venkatasubramanian has been inducted into the Board of the Company as Non - Executive, Independent Director with effect from March 31, 2014.

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that the Board of Directors of the Company at its meeting held on March 31, 2014, have fixed the accounting period for the financial year 2013-14 for a period of 12 Months from October 01, 2013 to September 30, 2014.

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange that Industrial Development Bank of India has withdrawn the nomination of Shri K. Biju George and instead appointed Shri T. A. Ganesh, General Manager, IDBI Bank Ltd, Chennai as its nominee on the Board of Orchid Chemicals and Pharmaceuticals Limited with effect from March 21, 2014.

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange that the Board of Directors at its meeting held on March 14,2014 has accepted the Letter of Approval (LOA) dated March 10, 2014 issued by Corporate Debt Restructuring Empowered Group (CDR EG) approving the Corporate Debt Restructuring proposal submitted by the Company.

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange regarding Press Release dated February 11, 2014 titled "Orchid Pharma registers turnover of Rs. 372 crore in Q1 FY14, an increase of 19% YoY, EBITDA of Rs. 109 Cr. and EBIT of Rs. 52 Cr."

Orchid Chemicals & Pharmaceuticals Limited has submitted to the exchange the standalone financial results for the period ended 31-dec-2013.

Orchid Chemicals & Pharmaceuticals Limited has informed that the Register of Companies (ROC), Chennai, Tamil Nadu has granted approval for the extension for holding the Annual General Meeting (AGM) of OCPL for the financial year 2012-13 (18 months) by a period of 3(three) months i.e. upto March 19, 2014.

Orchid Chemicals & Pharmaceuticals Limited has submitted to the exchange the standalone & consolidated financial results for the period ended 30-sep-2013.

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange regarding the press release with respect to the financial results for the period ended September 30,2013

Orchid Chemicals & Pharmaceuticals Limited has submitted to the Exchange the Standalone Financial Results along with the Limited Review Report for the period ended June 30,2013.

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange that Prof. Bala V Balachandran has resigned from the Board of the Company and Shri Sundaram Yuvaraj has been inducted into the Board of Orchid Chemicals and Phamaceuticals Limited with effect from August 14, 2013.

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange regarding the press release in-connection with the financial results for the quarter ended June 30, 2013.

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange that the Registrar of Companies vide its order dated July 09, 2013 has granted its approval for extension of financial year 2012-13 for a period of six months i.e. upto September 30, 2013 . Accordingly, the financial year 2012-13 will be of 18 months from April 01, 2012 to September 30, 2013.

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange regarding Extension of Financial Year 2012-2013 upto 18 months

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange vide letter dated June 21, 2013 regarding "Reference to CDR Cell (Corporate Debt Restructuring Scheme)".

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange that Orchid's Oral Formulations facility at Irungattukottai near chennai was successfully inspected and accepted by the USFDA without any observations.

Orchid Chemicals & Pharmaceuticals Limited has submitted to the Exchange the Standalone Financial Results along with the Limited Review Report for the period ended March 31,2013.

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange regarding Press Release dated May 15, 2013 titled "Orchid Pharma registers turnover od Rs.268 crores in Q4 FY13"

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange regarding the Outcome of Board Meeting of the Company held on April 17, 2013.

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange regarding a press release dated April 18, 2013 titled "Orchid enters into strategic partnership with Allecra Therapeutics for development of noval antibiotics".

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange that In accordance with Clause 49 of the Listing Agreement , the Company wishes to inform that Orchid's Cephalosporin API manufacturing complex located in Alathur, Chennai has successfully cleared the USFDA inspection that it went through. The facility manufactures a range of oral and sterile Cephalosporin APIs and caters to the developed markets like USA, Europe and Japan.

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange that Orchid's Cephalosporin API manufacturing complex located in Alathur, Chennai has successfully cleared the USFDA inspection that it went through. The facility manufactures a range of oral and sterile Cephalosporin APIs and caters to the developed markets like USA, Europe and Japan.

R. Vijayalakshmi has submitted to the Exchange vide letter dated April 04, 2013 a copy of Disclosure in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

K. Raghavendra Rao has submitted to the Exchange vide letter dated March 15, 2013 a copy of Disclosure in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Orchid Chemicals & Pharmaceuticals Limited has submitted to the Exchange the Standalone Financial Results along with the Limited Review Report for the period ended December 31,2012.

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange regarding a press release dated February 13, 2013, titled "Orchid Pharma registers turnover of Rs 322 crore in Q3 FY13".

K Raghavendra Rao has submitted to the Exchange vide letter dated January 23, 2013 a copy of Disclosure in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

K Raghavendra Rao has submitted to the Exchange vide its letter dated January 04, 2013 a copy of Disclosure in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

R. Vijayalakshmi has submitted to the Exchange vide letter dated December 28, 2012 a copy of Disclosure in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

K. Raghavendra Rao has submitted to the Exchange vide letter dated December 21, 2012 a copy of Disclosure in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange that Mrs. Bhoomijha Murali, Sr. General Manager- Legal & Company Secretary has resigned, and relieved from the services of the Company with effect from the closing hours of November 30, 2012. Mr. L Chandrasekar, Executive Vice President - Finance & Secretary has taken over as the Company Secretary from December 01, 2012. Mr. L Chandrasekar, will also be the Compliance Officer of the Company.

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange that Shri Bharat D Shah and Shri Deepak Vaidya, Directors have resigned from the Board of the Company with effect from November 15, 2012 and November 19, 2012 respectively.

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 09, 2012, titled "Orchid Pharma registers sale of Rs 330 crore in Q2 FY13".

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 09, 2012, titled "Orchid Pharma to exit its Chinese JV".